Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome.
OBJECTIVE
Osteocalcin has been reported to influence insulin secretion in experimental animals. We investigated whether serum osteocalcin was associated with measures of insulin resistance, circulating adipokine levels, and the presence of metabolic syndrome (MetSyn).


RESULTS
Serum osteocalcin was measured by solid-phase sandwich immunoassay in 1284 blacks (64+/-9 years; 71% women) and 1209 non-Hispanic whites (59+/-10 years; 57% women) belonging to hypertensive sibships. MetSyn was defined per Adult Treatment Panel III criteria. The prevalence of MetSyn was 50% in blacks and 49% in non-Hispanic whites. In each ethnic group, after adjustment for age and gender, osteocalcin levels were inversely correlated with body mass index, fasting glucose and insulin, homeostasis model assessment of insulin resistance, triglycerides, and leptin, and positively correlated with adiponectin (P<0.001 for each variable). In multivariable regression analyses that adjusted for age, gender, smoking, serum creatinine, and statin and estrogen use, osteocalcin levels in the highest quartile (compared with the lowest quartile) were associated with a lower odds ratio (OR) of having MetSyn: OR (95% CI) in blacks, 0.33 (0.23 to 0.46); OR in non-Hispanic whites, 0.43 (0.31 to 0.63).


CONCLUSIONS
Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of MetSyn, suggesting a novel cross-talk between bone and adipose tissue.
Saleem
Umer
U
Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Mosley
Thomas H
TH
Kullo
Iftikhar J
IJ
D054392:Adipokines / Q000097:blood*; D052242:Adiponectin / Q000097:blood; D001741:Black or African American; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D016009:Chi-Square Distribution; D004797:Enzyme-Linked Immunosorbent Assay; D005215:Fasting / Q000097:blood; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000208:ethnology; D020738:Leptin / Q000097:blood; D016015:Logistic Models; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000208:ethnology / Q000503:physiopathology; D008875:Middle Aged; D008910:Minnesota / Q000453:epidemiology; D008922:Mississippi / Q000453:epidemiology; D016017:Odds Ratio; D015675:Osteocalcin / Q000097:blood*; D018570:Risk Assessment; D012307:Risk Factors; D044465:White People
C499918:ADIPOQ protein, human; D054392:Adipokines; D052242:Adiponectin; D015415:Biomarkers; D001786:Blood Glucose; D007328:Insulin; D020738:Leptin; D015675:Osteocalcin
J Clin Endocrinol Metab. 2009 Mar;94(3):827-32
19088165
J Clin Endocrinol Metab. 2007 Apr;92(4):1517-23
17264180
Nat Rev Rheumatol. 2009 Jul;5(7):365-72
19468288
Science. 2000 Sep 1;289(5484):1501-4
10968779
J Clin Endocrinol Metab. 2004 Mar;89(3):1481-4
15001651
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5266-70
18362359
Trends Endocrinol Metab. 2008 Jul;19(5):161-6
18407515
JAMA. 2002 Dec 4;288(21):2709-16
12460094
JAMA. 2001 May 16;285(19):2486-97
11368702
Bone. 2008 May;42(5):837-40
18295563
Diabetologia. 1985 Jul;28(7):412-9
3899825
J Clin Endocrinol Metab. 2007 May;92(5):1640-6
17299077
Calcif Tissue Int. 1998 Aug;63(2):107-11
9685513
Biometrics. 1986 Mar;42(1):121-30
3719049
PLoS One. 2010 Feb 05;5(2):e9065
20140090
J Clin Endocrinol Metab. 2009 Jan;94(1):45-9
18984661
Cell. 2007 Aug 10;130(3):456-69
17693256
Nature. 2003 Jun 12;423(6941):762-9
12802337
Hypertension. 2002 Jan;39(1):3-9
11799070
Circulation. 2004 Jan 27;109(3):433-8
14744958
Diabetes. 2002 Oct;51(10):3120-7
12351457
Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):629-36
18174459
Ann Clin Biochem. 2000 Jul;37 ( Pt 4):432-46
10902858
Nat Med. 2001 Aug;7(8):941-6
11479627
J Clin Endocrinol Metab. 1987 Jan;64(1):59-61
2878010
J Bone Miner Res. 2009 May;24(5):785-91
19063687